What is Bangkok Genomics Innovation PCL OCF Margin %?
Bangkok Genomics Innovation PCLBKK:BKGI 45 OCF Margin % is -72.02% as of Dec. 2025. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks worse than 72.41% on this metric.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's OCF Margin % or its related term are showing as below:
BKK:BKGI'
s OCF Margin % Range Over the Past 10 Years
Min: -24.32 Med: 12.05 Max: 29.28
Current: -24.32
During the past 7 years, the highest OCF Margin % of Bangkok Genomics Innovation PCL was 29.28%. The lowest was -24.32%. And the median was 12.05%.
BKK:BKGI's OCF Margin % is ranked worse than 72.41% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.67
vs BKK:BKGI: -24.32
Bangkok Genomics Innovation PCL OCF Margin % Related Terms
Bangkok Genomics Innovation PCL OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a OCF Margin % of -72.02% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bangkok Genomics Innovation PCL and its competitors. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #147 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 72.4%.
Is Bangkok Genomics Innovation PCL's OCF Margin % too high?
Bangkok Genomics Innovation PCL's current OCF Margin % is -72.02%. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #147 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #147 out of 203 companies for OCF Margin %. This places Bangkok Genomics Innovation PCL in the lower half of its industry. The industry median OCF Margin % is 4.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.67, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current OCF Margin % is -72.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current OCF Margin % of -72.02%. The current OCF Margin % is -72.02%. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current OCF Margin % is -72.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL Business Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
